Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

Dilly_Due Nov. 14 at 4:25 PM

$DMAC $VXRT Simply lovin it! Upgrades on both! Double digit gains on both today! Congrats to all the longs!

0 · Reply

Sicksir Nov. 14 at 3:09 PM

$DMAC $25 PT from the top analyst in biotech

1 · Reply

JarvisFlow Nov. 14 at 2:29 PM

Cantor Fitzgerald updates rating for DiaMedica Therapeutics ( $DMAC ) to Overweight, target set at 25.

1 · Reply

BioGem Nov. 14 at 11:04 AM

$DMAC I will consider a short on this name, many critical negatives: -Expect heavier losses and cash burn soon as they are launching the early stages in pre-E and other pregnancy trials. -Delay by half a year for their stroke trial = more waiting and cash burn. -Cash expected by December is 45M, which is not great = expect an offering in 2026. -Late catalysts with no data before 9-12 months from now = opportunity cost = bored buyers will sell in the meantime. -Expect analysts to drop the price targets due to the delays. -Short interest is increasing.

1 · Reply

stockwitsuser2449 Nov. 13 at 9:15 PM

$DMAC

0 · Reply

Relee187200 Nov. 13 at 3:23 PM

$DMAC My God. What happened?

2 · Reply

Sukitt Nov. 13 at 2:41 PM

$DMAC Someone not happy about runway could be a buying opportunity.

1 · Reply

Tjcmd Nov. 13 at 1:25 PM

$DMAC what’s up with the CC?

2 · Reply

justiceforb_85 Nov. 13 at 12:39 AM

$DMAC bit slower progress on DM199 in AIS (with interim analysis in H2 '26) but do believe the promise is there.

0 · Reply

Sicksir Nov. 12 at 11:40 PM

$DMAC - Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks - Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia - AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 - $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027

0 · Reply

DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:30 PM EST - 2 days ago

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 10, 2025, 8:15 AM EST - 4 days ago

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:15 PM EST - 8 days ago

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

Sep 29, 2025, 4:15 PM EDT - 6 weeks ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 5, 2025, 8:30 AM EDT - 2 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:23 AM EDT - 2 months ago

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 3:58 PM EDT - 3 months ago

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

Aug 13, 2025, 11:36 AM EDT - 3 months ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:15 PM EDT - 3 months ago

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 6, 2025, 8:00 AM EDT - 3 months ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 5, 2025, 4:15 PM EDT - 3 months ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

Jul 23, 2025, 4:30 PM EDT - 4 months ago

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

Jul 21, 2025, 8:00 AM EDT - 4 months ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

Jul 17, 2025, 8:00 AM EDT - 4 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025, 8:30 AM EDT - 5 months ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025, 8:30 AM EDT - 6 months ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025, 9:00 AM EDT - 6 months ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 6 months ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 11:05 AM EDT - 6 months ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:30 PM EDT - 6 months ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 6 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 6 months ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 18, 2025, 10:27 AM EDT - 8 months ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:30 PM EDT - 8 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 8 months ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 9 months ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 9 months ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 9 months ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 12:49 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:20 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 2:48 PM EDT - 1 year ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 11, 2024, 4:49 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Apr 17, 2024, 4:08 PM EDT - 1 year ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 20, 2024, 4:14 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Dilly_Due Nov. 14 at 4:25 PM

$DMAC $VXRT Simply lovin it! Upgrades on both! Double digit gains on both today! Congrats to all the longs!

0 · Reply

Sicksir Nov. 14 at 3:09 PM

$DMAC $25 PT from the top analyst in biotech

1 · Reply

JarvisFlow Nov. 14 at 2:29 PM

Cantor Fitzgerald updates rating for DiaMedica Therapeutics ( $DMAC ) to Overweight, target set at 25.

1 · Reply

BioGem Nov. 14 at 11:04 AM

1 · Reply

stockwitsuser2449 Nov. 13 at 9:15 PM

$DMAC

0 · Reply

Relee187200 Nov. 13 at 3:23 PM

$DMAC My God. What happened?

2 · Reply

Sukitt Nov. 13 at 2:41 PM

$DMAC Someone not happy about runway could be a buying opportunity.

1 · Reply

Tjcmd Nov. 13 at 1:25 PM

$DMAC what’s up with the CC?

2 · Reply

justiceforb_85 Nov. 13 at 12:39 AM

$DMAC bit slower progress on DM199 in AIS (with interim analysis in H2 '26) but do believe the promise is there.

0 · Reply

Sicksir Nov. 12 at 11:40 PM

0 · Reply

Relee187200 Nov. 12 at 11:00 PM

$DMAC What were the earnings??

0 · Reply

Relee187200 Nov. 12 at 10:16 PM

$DMAC Where are the earnings?

0 · Reply

Sicksir Nov. 12 at 3:48 PM

$DMAC business update today AH. Exciting!

1 · Reply

Dilly_Due Nov. 9 at 6:39 PM

$DMAC $VXRT Retail ownership/presense on Stocktwits of DiaMedica I currently own two biomedical stocks, DiaMedica and Vaxart. See my previous post on why I feel DiaMedica is worth a look. I've followed Vaxart since 2000 and the start of covid and over time developed a tremendous respect and learned a ton from many the regularly VXRT posters on Stocktwits. I've been following DiaMedica only since Leon Copperman recommended it on CNBC a few months ago and after some due diligence took a position in the stock. I loaded more last week when a key gap was filled. Having had friends and relatives affected by Preeclampsia and stroke tells me how impactful any advancement in treatments for these conditions would be. I'd love to see increased retail participation and discussion here on DiaMedica. From what I've learned many retail investors are extremely well informed, intelligent and "move the needle" for retail to keep up with institutional. JMHO. Do that DD.

2 · Reply

Dilly_Due Nov. 8 at 4:24 PM

$DMAC @Losjuarez @Sukitt I'll take a shot at answering why in my own humble opinion. Do your own DD. Source nasdaq website. 1) Signficant insider buyin within past 3 mos at $6. Friday close $5.92. https://www.nasdaq.com/market-activity/stocks/dmac/insider-activity 2) Highest short interest since last posted date of 11/15/2024. More than 18 days to cover at current avg. volume. https://www.nasdaq.com/market-activity/stocks/dmac/short-interest 3) High insider ownership 45.98% (source Fintel) 4) Institutional ownership rising at currently at 17% (source Fintel) 5) Earnings report 11/12/25 after close. Fingers crossed for good news. 6) Two upcoming presentations following earnings. Fingers crossed for good news. Go DMAC! Moms, babies and stroke sufferers need this to work!

0 · Reply

Sukitt Nov. 6 at 5:45 PM

$DMAC Buy up folks. Today's dip is a gift.

1 · Reply

Bartjw Nov. 5 at 8:48 PM

$DMAC https://www.drugtargetreview.com/article/190279/recombinant-klk1-the-next-step-in-stroke-and-preeclampsia-treatment/

0 · Reply

Relee187200 Nov. 5 at 8:26 PM

$DMAC When is next catalyst?

0 · Reply

BEATOFtheMARKET Nov. 5 at 6:47 PM

$DLN $DLS $DLX $DMAC $DMAT 🔥

0 · Reply

Sicksir Oct. 30 at 1:36 PM

$DMAC TD Cowen initiates BUY

0 · Reply

NowWeKnow Oct. 24 at 6:32 PM

$DMAC Dataroma pick of the week! Who knows something 🤨 If you don't tell me I'll report you to RFK Jr. so he can read you Harry Potter with that voice at night

1 · Reply

RealAvidTrader Oct. 23 at 2:33 PM

$DMAC Insiders Are Betting BIG On This Stock Breakout! https://youtu.be/t5WAqWImUms

0 · Reply

Market Cap	280.15M
Revenue (ttm)	0.00
Net Income (ttm)	-24.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	637,100
Avg Vol	365,668
Day's Range	N/A - N/A
Shares Out	51.69M
Stochastic %K	41%
Beta	1.42
Analysts	Strong Sell
Price Target	$12.33